Japan's pharma giant Astellas chooses Copenhagen as base for Nordic growth  

2005.07.27
Astellas, one of the world's largest pharmaceutical groups, has chosen to place its Nordic headquarters in Copenhagen and plans to make it the platform for strong growth in the Nordic region

Astellas, the second largest pharmaceutical company in Japan formed after a merger between Yamanouchi and Fujisawa in April, has chosen to place its Nordic headquarters in Copenhagen and plans to make it the platform for strong growth in the Nordic region. The objective is to be among the ten largest pharmaceutical companies in the region in a few years.

Mats Persson, Nordic Chief Executive of Astellas says that Copenhagen is a strategically interesting location to place a Nordic headquarters, and that he believes in the synergies of being located in Medicon Valley. Astellas will focus on its three core businesses in transplantation, skin diseases and urological diseases: "We will be among the ten largest in approximately five years. It will happen both through our own research programmes and new products", says Mats Persson. He says that buying research programmes from Danish biotech companies in Medicon Valley could be involved.

Astellas' research budget is USD 1.3 bn, and revenues for 2005 are forecast at USD 7.3 bn. The company's top selling product is the blockbuster Prograf, a drug used for heart transplantation. In Europe, Astellas employs 3,000 people. The news is reported by national daily newspaper Berlingske Tidende.

Link > Astellas 

Next step

Explore business cases

Please contact me

Name
Company
E-mail
Phone
How can we help you?

IDK
We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×